Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Is Inspiration Healthcare Group plc Building Fresh Momentum?

Daily Change:+0.50p (up 2.70%) as of the latest session

Ishan Mudgal | 12 August 2026

Is MDxHealth SA Facing Renewed Pressure?

Daily Change:-$0.0129 (down 2.84%) as of the latest session

Ishan Mudgal | 12 August 2026

Is Palatin Technologies, Inc. Building Fresh Momentum?

Daily Change:+$0.0500 (up 0.68%) as of the latest session

Ishan Mudgal | 12 August 2026

Is RUA Life Sciences plc Building Fresh Momentum?

Daily Change:+4.40p (up 17.96%) as of the latest session

Ishan Mudgal | 12 August 2026

Is SINTX Technologies, Inc. Building Fresh Momentum?

Daily Change:+$0.0700 (up 4.12%) as of the latest session

Ishan Mudgal | 12 August 2026

Is Soligenix, Inc. Building Fresh Momentum?

Daily Change:+$0.0090 (up 2.38%) as of the latest session

Ishan Mudgal | 12 August 2026

Is Tvardi Therapeutics, Inc. Building Fresh Momentum?

Daily Change:+$0.0100 (up 0.57%) as of the latest session

Ishan Mudgal | 12 August 2026

Verici DX: Could One Biotechnology Catalyst Transform This Tiny Healthcare Stock?

Verici Dx (LSE:VRCI) is a molecular diagnostics company trying to solve an expensive clinical problem: predicting and detecting when a transplanted kidney is being rejected. Its tests read the RNA signatures in a patient's blood to flag rejection risk earlier than a conventional biopsy, …

Divya Sood | 12 August 2026

AIM ImmunoTech: Is This Microcap One Major Catalyst Away From an Explosive Re-Rating?

AIM ImmunoTech (NYSE American: AIM) is a clinical-stage US biotechnology company whose fortunes hinge almost entirely on a single asset: Ampligen (rintatolimod), an immuno-modulator it is testing in cancer and other conditions. The current focus is pancreatic cancer, one of oncology's hardest-to-treat diseases, where …

Divya Sood | 12 August 2026

Moleculin Biotech: Could One Breakthrough Send This Tiny Stock Into Overdrive?

Moleculin Biotech, Inc. (Nasdaq: MBRX) is a Houston-based, clinical-stage pharmaceutical company whose lead drug candidate, Annamycin, is being tested in a pivotal trial for acute myeloid leukaemia (AML), an aggressive blood cancer. The company has no approved products and no product revenue; its entire …

Divya Sood | 12 August 2026
Support

Hi! How can we help you today?

Loading…